SCHEMBL21618237

SCHEMBL21618237

O=C1CCC(N2Cc3cc(OC4CCCCC4NCCC4CCOCC4)ccc3C2=O)C(=O)N1

nearest known ligand 0.53

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
IKZF2 Q9UKS7 10/20 0.53
WIZ O95785 6/20 0.48
CRBN Q96SW2 4/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21618146 1.00 IKZF2 (0.53) IKZF2WIZCRBN
SCHEMBL24079647 1.00 IKZF2 (0.53) IKZF2WIZCRBN
SCHEMBL21621793 1.00 IKZF2 (0.53) IKZF2WIZCRBN
SCHEMBL24080079 1.00 IKZF2 (0.53) IKZF2WIZCRBN
SCHEMBL30326879 1.00 IKZF2 (0.53) IKZF2WIZCRBN
SCHEMBL25998821 0.92 IKZF2 (0.44) IKZF2WIZCRBN
SCHEMBL24079798 0.92 IKZF2 (0.62) IKZF2WIZCRBN
SCHEMBL24079620 0.92 IKZF2 (0.62) IKZF2WIZCRBN
SCHEMBL21618042 0.92 IKZF2 (0.62) IKZF2WIZCRBN
SCHEMBL21618013 0.92 IKZF2 (0.62) IKZF2WIZCRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12570625-B2 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof NOVARTIS AG (CH) 2026-03-10 US claimed
EP-3820573-B1 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF IKAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES NOVARTIS AG (CH) 2023-08-09 EP claimed
EP-3820573-A1 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF IKAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES Novartis AG (CH) 2021-05-19 EP claimed
CN-112261970-A 3- (5-hydroxy-1-oxoisoindolin-2-yl) piperidine-2, 6-dione derivatives and their use in the treatment of IKAROS family Zinc finger 2(IKZF2) dependent diseases 诺华股份有限公司 2021-01-22 CN claimed
WO-2020012334-A1 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF IKAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES NOVARTIS AG (CH) 2020-01-16 WO claimed
CN-116096862-A ZBTB32 inhibitors and uses thereof 诺华股份有限公司 2023-05-09 CN disclosed
EP-4165169-A1 ZBTB32 INHIBITORS AND USES THEREOF Novartis AG (CH) 2023-04-19 EP disclosed
US-20230067476-A1 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2023-03-02 US disclosed
US-11192877-B2 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof NOVARTIS AG (CH) 2021-12-07 US disclosed
WO-2020012334-A1 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF IKAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES NOVARTIS AG (CH) 2020-01-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12570625-B2 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof IKZF1, IKZF2, BCL6 IKZF2 2/4885WIZ 531/4885CRBN 148/4885
US-11192877-B2 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof XDH, HTR1D, RXFP1 IKZF2 3604/4885WIZ 1518/4885CRBN 3703/4885
US-20230067476-A1 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF XDH, HTR1D, RXFP1 IKZF2 3604/4885WIZ 1518/4885CRBN 3703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.